Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methoxsalen + methylprednisolone is a combination of two pharmaceutical agents, each with distinct mechanisms and indications. Methoxsalen is a naturally occurring furocoumarin and photosensitizer used primarily in conjunction with ultraviolet A (UVA) light in PUVA therapy to treat conditions such as psoriasis, vitiligo, and cutaneous T-cell lymphoma. It works by intercalating into DNA and forming cross-links upon UVA exposure, thereby inhibiting the proliferation of abnormal skin cells[1][4][7]. Methylprednisolone is a synthetic corticosteroid that mimics endogenous glucocorticoids produced by the adrenal glands. It exerts potent anti-inflammatory and immunosuppressive effects by modulating gene expression through the glucocorticoid receptor, leading to decreased production of pro-inflammatory cytokines. Methylprednisolone is indicated for various inflammatory and autoimmune disorders including arthritis, severe allergies, asthma, lupus, ulcerative colitis, certain cancers, and skin diseases[2][3][5]. The combination may be considered when both photochemotherapy (PUVA) and systemic immunosuppression are required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methoxsalen + methylprednisolone.